Andrew Hendifar

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3K citations · Full text

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

Michael J. Pishvaian, Edik M. Blais, Jonathan R. Brody et al. · The Lancet Oncology · 2020 · 517 citations

Prognostic Biomarkers, Pancreatic Cancer, Overall Survival +11

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma

Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock et al. · Journal of Clinical Oncology · 2017 · 467 citations

Nanotherapeutics, Pathology, Phase Ii Study +17

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Eric Van Cutsem, Margaret A. Tempero, Darren Sigal et al. · Journal of Clinical Oncology · 2020 · 404 citations · Full text

A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era

Daniel C. Allison, Scott C. Carney, Elke R. Ahlmann et al. · Sarcoma · 2012 · 402 citations · Full text

Bone Disease, Surgical Oncology, Oncology +14